3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
53
Neoplasm Metastasis
16
Carcinoma, Non-Small-Cell Lung
10
Neoplasms
7
Brain Neoplasms
5
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Neoplasms by Site
3
Melanoma
3
Glioma
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Breast Diseases
3
Sarcoma, Ewing
2
Recurrence
2
Pancreatic Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma
2
Glioblastoma
2
Advanced Cancer
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spinal Cord Neoplasms
1
Solid Tumor, Adult
1
Sarcoma
1
Rhabdomyosarcoma
1
Interventions
enzalutamide
5
abiraterone
3
Prednisone
3
Docetaxel
3
Abiraterone Acetate
3
relugolix
1
pembrolizumab
1
onvansertib
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
apalutamide
1
abemaciclib
1
Prednisolone
1
PF06821497
1
Methylprednisolone
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Metastatic Castration-Resistant Prostate Cancer
×
abemaciclib
×
Clear all
NCT04408924
2024-06-25
CYCLONE 1
Eli Lilly and Company
Phase 2
Completed
44 enrolled
21 charts